Kuros Biosciences (CSBTF) Financial Statements
Kuros Biosciences Financial Overview
Kuros Biosciences's market cap is currently $996.04M. The company's EPS TTM is $0.18; its P/E ratio is 114.03; Kuros Biosciences is estimated to report earnings on March 3, 2027, and the estimated EPS forecast is $0.10. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 121.30M | $ 75.56M | $ 33.56M | $ 17.99M | $ 13.81M |
| Gross Profit | $ 104.79M | $ 62.03M | $ 23.94M | $ 10.77M | $ 10.07M |
| Operating Income | $ 7.33M | $ -5.00M | $ -13.19M | $ -13.45M | $ -8.77M |
| EBITDA | $ 10.01M | $ -537.00K | $ -6.84M | $ -8.84M | $ -5.29M |
| Net Income | $ 2.12M | $ -3.72M | $ -13.73M | $ -14.60M | $ -7.54M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 15.66M | $ 17.46M | $ 14.21M | $ 24.07M | $ 28.62M |
| Total Assets | $ 107.21M | $ 84.54M | $ 71.46M | $ 82.95M | $ 91.34M |
| Total Debt | $ 3.94M | $ 1.79M | $ 2.14M | $ 1.91M | $ 8.93M |
| Net Debt | $ -11.72M | $ -15.67M | $ -12.06M | $ -22.15M | $ -19.70M |
| Total Liabilities | $ 40.28M | $ 25.79M | $ 14.75M | $ 14.09M | $ 14.36M |
| Stockholders' Equity | $ 66.93M | $ 58.75M | $ 56.71M | $ 68.86M | $ 76.98M |
| Cash Flow | |||||
| Free Cash Flow | $ -2.40M | $ 2.03M | $ -9.17M | $ -7.75M | $ -5.83M |
| Operating Cash Flow | $ -377.87K | $ 3.14M | $ -8.84M | $ -7.35M | $ -5.45M |
| Investing Cash Flow | $ -2.03M | $ -1.11M | $ -326.00K | $ -400.00K | $ -374.00K |
| Financing Cash Flow | $ 1.17M | $ 1.34M | $ -171.00K | $ 3.22M | $ 6.08M |
Currency in CHF